These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2116583)

  • 1. A review of cost-effectiveness analyses.
    Hurley S
    Med J Aust; 1990 Aug; 153(S1):S20-3. PubMed ID: 2116583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What can be concluded from the Oxcheck and British family heart studies: commentary on cost effectiveness analyses.
    Wonderling D; Langham S; Buxton M; Normand C; McDermott C
    BMJ; 1996 May; 312(7041):1274-8. PubMed ID: 8634618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a microsimulation economic model to evaluate the disease burden associated with smoking and the cost-effectiveness of tobacco control interventions in Latin America.
    Pichon-Riviere A; Augustovski F; Bardach A; Colantonio L;
    Value Health; 2011; 14(5 Suppl 1):S51-9. PubMed ID: 21839900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
    Hristova L; Hakama M
    Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of WISEWOMAN, a program aimed at reducing heart disease risk among low-income women.
    Finkelstein EA; Khavjou O; Will JC
    J Womens Health (Larchmt); 2006 May; 15(4):379-89. PubMed ID: 16724886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis with defined budget: how to distribute resources for the prevention of cardiovascular disease?
    Lindholm L; Hallgren CG; Boman K; Markgren K; Weinehall L; Ogren JE
    Health Policy; 1999 Sep; 48(3):155-70. PubMed ID: 11067036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of effective screening strategies for cardiovascular disease prevention in a developing country: using cardiovascular risk-estimation and risk-reduction tools for policy recommendations.
    Selvarajah S; Haniff J; Kaur G; Guat Hiong T; Bujang A; Chee Cheong K; Bots ML
    BMC Cardiovasc Disord; 2013 Feb; 13():10. PubMed ID: 23442728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
    Boersma C; Gansevoort RT; Pechlivanoglou P; Visser ST; van Toly FF; de Jong-van den Berg LT; de Jong PE; Postma MJ;
    Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of cardiovascular disease prevention strategies: a perspective on EU food based dietary guidelines.
    Brunner E; Cohen D; Toon L
    Public Health Nutr; 2001 Apr; 4(2B):711-5. PubMed ID: 11683566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Cancer Screening: Health and Costs in Life Years Gained.
    Ratushnyak S; Hoogendoorn M; van Baal PHM
    Am J Prev Med; 2019 Dec; 57(6):792-799. PubMed ID: 31753260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of a community-based cardiovascular disease prevention intervention in medically underserved rural areas.
    Wang H; Kenkel D; Graham ML; Paul LC; Folta SC; Nelson ME; Strogatz D; Seguin RA
    BMC Health Serv Res; 2019 May; 19(1):315. PubMed ID: 31096977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention may be more expensive than cure.
    Butler JA
    J R Soc Med; 1993 Jun; 86(6):341-4. PubMed ID: 8315628
    [No Abstract]   [Full Text] [Related]  

  • 14. Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia.
    Blake GJ; Ridker PM; Kuntz KM
    Am J Med; 2003 Apr; 114(6):485-94. PubMed ID: 12727581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How cost-effective are new preventive strategies for cardiovascular disease?
    Probstfield JL
    Am J Cardiol; 2003 May; 91(10A):22G-27G. PubMed ID: 12781905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-effectiveness analysis of cervical cancer screening: health policy implications.
    Gyrd-Hansen D; Hølund B; Andersen P
    Health Policy; 1995 Oct; 34(1):35-51. PubMed ID: 10151964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissecting cost-effectiveness analysis for preventive interventions: a guide for decision makers.
    Teutsch SM; Murray JF
    Am J Manag Care; 1999 Mar; 5(3):301-5. PubMed ID: 10351026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is cost-effectiveness analysis?
    Evans DB
    Med J Aust; 1990 Aug; 153(S1):S7-9. PubMed ID: 2116585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the prevention of renal and vascular endstage disease (PREVEND) study and the prevention of renal and vascular endstage disease intervention trial (PREVEND IT).
    Atthobari J; Asselbergs FW; Boersma C; de Vries R; Hillege HL; van Gilst WH; Gansevoort RT; de Jong PE; de Jong-van den Berg LT; Postma MJ;
    Clin Ther; 2006 Mar; 28(3):432-44. PubMed ID: 16750458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening.
    de Kok IM; Polder JJ; Habbema JD; Berkers LM; Meerding WJ; Rebolj M; van Ballegooijen M
    Br J Cancer; 2009 Apr; 100(8):1240-4. PubMed ID: 19367281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.